Lucijanić, M. i Kušec, R. (2021). Ruxolitinib withdrawal due to the COVID-19. Leukemia, 35. (4), 1218. doi: 10.1038/s41375-021-01214-4
Lucijanić, Marko i Rajko Kušec. "Ruxolitinib withdrawal due to the COVID-19." Leukemia, vol. 35, br. 4, 2021, str. 1218. https://doi.org/10.1038/s41375-021-01214-4
Lucijanić, Marko i Rajko Kušec. "Ruxolitinib withdrawal due to the COVID-19." Leukemia 35, br. 4 (2021): 1218. https://doi.org/10.1038/s41375-021-01214-4
Lucijanić, M. i Kušec, R. (2021) 'Ruxolitinib withdrawal due to the COVID-19', Leukemia, 35(4), str. 1218. doi: 10.1038/s41375-021-01214-4
Lucijanić M, Kušec R. Ruxolitinib withdrawal due to the COVID-19. Leukemia [Internet]. 17.03.2021. [pristupljeno 01.12.2024.];35(4):1218. doi: 10.1038/s41375-021-01214-4
M. Lucijanić i R. Kušec, "Ruxolitinib withdrawal due to the COVID-19", Leukemia, vol. 35, br. 4, str. 1218, Ožujak 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:466215. [Citirano: 01.12.2024.]